p-Toluenesulfonamide

171.21700

171.22

200-741-1

I8266RI90M

1557

9908

DTXSID8029105

Monoclinic plates (w+2)|White leaflets

2935009090

68.54000

0.8

DryPowder

1.271 g/cm3

138.5 °C

214 °C @ Press: 9.98 Torr

202ºC

1.564

Solubility in water, g/100ml at 25°C: 0.316

Keep container tightly closed in a dry and well-ventilated place.

Vapour pressure at 25°C: negligible

Henry's Law constant = 4.70X10-7 atm-cu m/mole at 25 °C (est)

pKa = 10.17 at 20 °C

Monoclinic plates /Dihydrate/|Hydroxyl radical reaction rate constant = 1.2X10-12 cu cm/molecule-sec at 25 °C (est)

III

NONH for all modes of transport

1

R36

S26

XT5075000

Xi

Separated from strong oxidants, acids and bases.

Compatible with polyvinyl butyral.

P305 + P351 + P338

H319

SRP: Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in air, soil or water; effects on animal, aquatic and plant life; and conformance with environmental and public health regulations. If it is possible or reasonable use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination.|Product: Offer surplus and non-recyclable solutions to a licensed disposal company. Contaminated packaging: Dispose of as unused product.

Incompatible materials: Strong oxidizing agents, Strong bases.

o- and p-Toluene sulfonamide is an indirect food additive for use as a component of adhesives. /o- and p-Toluene sulfonamide/

Combustible. Gives off irritating or toxic fumes (or gases) in a fire.

|Danger|H315 (14.68%): Causes skin irritation [Warning Skin corrosion/irritation]|P260, P264, P271, P280, P284, P302+P352, P304+P340, P305+P351+P338, P310, P320, P321, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 216 companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Eye/face protection: Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).|Skin protection: Handle with gloves.|Body Protection: Choose body protection in relation to its type, to the concentration and amount of dangerous substances, and to the specific work-place.|Respiratory protection: For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator. For higher level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Combustible.

Suitable extinguishing media: Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.|Advice for firefighters: Wear self-contained breathing apparatus for firefighting if necessary.

Personal protection: particulate filter respirator adapted to the airborne concentration of the substance. Sweep spilled substance into covered containers. If appropriate, moisten first to prevent dusting.|ACCIDENTAL RELEASE MEASURES: Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Avoid breathing dust. Environmental precautions: Do not let product enter drains. Methods and materials for containment and cleaning up: Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed containers for disposal.

ACCIDENTAL RELEASE MEASURES: Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Avoid breathing dust. Environmental precautions: Do not let product enter drains.|Precautions for safe handling: Avoid formation of dust and aerosols.Further processing of solid materials may result in the formation of combustible dusts. The potential for combustible dust formation should be taken into consideration before additional processing occurs. Provide appropriate exhaust ventilation at places where dust is formed.|Appropriate engineering controls: Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday.|SRP: Local exhaust ventilation should be applied wherever there is an incidence of point source emissions or dispersion of regulated contaminants in the work area. Ventilation control of the contaminant as close to its point of generation is both the most economical and safest method to minimize personnel exposure to airborne contaminants. Ensure that the local ventilation moves the contaminant away from the worker.

Personal protection: particulate filter respirator adapted to the airborne concentration of the substance. Sweep spilled substance into covered containers. If appropriate, moisten first to prevent dusting.

Separated from strong oxidants, acids and bases.

A nuisance-causing concentration of airborne particles can be reached quickly when dispersed.

May cause mechanical irritation to the eyes.

NO open flames.

Use ventilation.

Protective gloves.

Wear safety goggles.

p-Toluenesulfonamide has been identified in the effluent from the nonferrous metals industry (22 ng/uL extract) and the printing and publishing industry at 19 and 841 ng/uL, respectively(1). p-Toluenesulfonamide was identified, not quantified, as a contaminant found in advanced treatment water in Pomona, CA on 9/24/74(2). p-Toluenesulfonamide was identified in runoff samples from 6 crop fields irrigated with treated effluent and effluent-dominated stream water; concentrations reported in the runoff were <650 ng/L, WWTP effluent 115-184 ng/L, and effluent-dominated stream water <630 ng/L(3).|... The presence of benzosulfonamides (BeSAs) has been evaluated during seven consecutive days in influent and effluent samples from the wastewater treatment plant of Athens, Greece. o-TSA and p-TSA were detected in 100% of the samples, while BSA was detected in all the influents and in 43% of the effluents. All three compounds were determined in relevant concentrations (up to 1.4 ug/L in the case of p-TSA), constituting the first evidence of the presence of these compounds in Greece, and contributing to the scarce occurrence data. Removal efficiencies of BeSAs during wastewater treatment was also assessed and discussed. In this regard, different behaviors were observed: while BSA and p-TSA were removed in different rates, o-TSA was formed during wastewater treatment. A daily load of 0.48 kg of o-TSA and 0.47 kg of p-TSA was discarded in the receiving Saronikos Gulf.

A novel approach was investigated for the assessment of leaching from a one-component polyurethane (1C-PU) coating used for hydraulic structures using nontarget analysis via LC-QTOF-MS. Leaching behavior of the 1C-PU coating was studied using experiments in which the coating was exposed to water for defined periods (6 h, 24 h, 3 d, 14 d). Three hardening durations for the 1C-PU coating were tested (0 h, 24 h, 14 d) as well as two water matrices (ultrapure water and river water), including a successive water renewal. Dissolved organic carbon, total nitrogen bound and nontarget measurements via LC-QTOF-MS showed that under all tested conditions organic substances were leached out of the 1C-PU coating. The shorter the hardening duration and the longer the leaching duration, the higher were the number and quantities of the eluted substances, while the influence of the water matrix was minor with respect to substance elution. Based on the MS2 spectra from the LC-QTOF-MS measurements, 30 substances released from the 1C-PU coating were tentatively identified. These substances belong to five chemical groups: derivatives of (i) N-(tosyl)carbamate, (ii) p-toluenesulfonamide (PTSA), (iii) 4,4'-methylenediphenyl diisocyanate (4,4'-MDI), (iv) toluenediisocyanate (TDI), and (v) oligo(ethylene) ([C2H4O]n) as well as p-toluenesulfonic acid. The identity of seven substances was confirmed by authentic reference standards, all of which exhibited an elevated bacterial toxicity to Aliivibrio fischeri. p-Toluenesulfonic acid was present in a German canal (Teltowkanal) with concentrations of up to 11 ug/L.|Nail polish that has completely dried on the fingernails contains water-soluble components that attain the skin during extensive but transient contact. This was proven by water extraction of thin layers of nail polish that had been painted onto glass plates and allowed to dry for 3 days. Comparing the isolated fractions and compounds with known nail polish ingredients revealed that the water-soluble substances are para- and ortho-toluenesulfonamide, dibutyl phthalate and 3 constituents of toluenesulfonamide-formaldehyde resin (TS-F-R), which is the basic material of almost all nail polishes sold worldwide. 12 female patients with proven nail polish allergy were patch tested with 21 nail polish components, including those isolated. Only 2 fractions were positive. These contained a monomer and a dimer created during condensation of TS-F-R. Their structures were elucidated. The 3rd compound, a trimer, remained negative, except in 1 case.

IDENTIFICATION AND USE: p-Toluenesulfonamide is a solid. It is used in organic synthesis, in plasticizers and resins, and as a fungicide and mildewicide in paints and coatings. It has been used as experimental therapy. HUMAN STUDIES: It is known as a common contact allergen. ANIMAL STUDIES: No treatment-related effects were observed in a 90 day feeding study on dogs exposed to doses up to 3000 mg/kg feed of a mixture of p-toluenesulfonamide (68%) and ortho-toluenesulfonamide (32%), equivalent to 75 mg/kg bw/day. In a 90 day feeding study, rats were exposed to diets containing 0, 300, 1000 or 3000 mg/kg feed of mixture of p-toluenesulfonamide (68%) and ortho-toluenesulfonamide (32%), equivalent to approximately 15, 50 or 150 mg/kg bw/day. A slight reduction of weight gain and food consumption was present at 3000 mg/kg feed as the only treatment-related effects. Pregnant rats were treated by gavage on gestational days 6-15 with 0, 50, 250, or 500 mg/kg bw of a mixture of p-toluenesulfonamide (68%) and ortho-toluenesulfonamide (32%). At 250 and 500 mg/kg bw maternal weight gain was significantly reduced during the treatment period. At the same dose levels, postimplantation loss demonstrated a dose-related increase and fetal weight was reduced. No teratogenic effect was observed. p-Toluenesulfonamide was studied for mutagenic potential with Salmonella typhimurium/microsome test, basic-test in Drosophila melanogaster, and micronucleus test in mice. No test revealed mutagenic activity.

LD50 Rat oral 2400 mg/kg bw /Mixture of ortho-toluenesulfonamide (41%) and para-toluenesulfonamide (51%)/|LD50 Rat oral 2330 mg/kg bw|LD50 Rat oral >2000 mg/kg|LD50 Mouse oral 400 mg/kg|LD50 Mouse ip 250 mg/kg

p-Toluenesulfonamide's production and use in organic synthesis, in plasticizers and resins, and as a fungicide and mildewicide in paints and coatings(1), may result in its release to the environment through various waste streams(SRC).

TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 35(SRC), determined from a log Kow of 0.82(2) and a regression-derived equation(3), indicates that p-toluenesulfonamide is expected to have very high mobility in soil(SRC). Volatilization of p-toluenesulfonamide from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 4.7X10-7 atm-cu m/mole(SRC), using a fragment constant estimation method(3). p-Toluenesulfonamide is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 9.6X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(3). A 3% of theoretical BOD using activated sludge in the Japanese MITI test(4) suggests that biodegradation is not an important environmental fate process in soil(SRC).|AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 35(SRC), determined from a log Kow of 0.82(2) and a regression-derived equation(3), indicates that p-toluenesulfonamide is not expected to adsorb to suspended solids and sediment(SRC). Volatilization of p-toluenesulfonamide from moist soil surfaces is not expected to be an important fate process(SRC) given an estimated Henry's Law constant of 4.7X10-7 atm-cu m/mole(SRC), using a fragment constant estimation method(3). According to a classification scheme(4), an estimated BCF of 3.2(SRC), from its log Kow(2) and a regression-derived equation(3), suggests the potential for bioconcentration in aquatic organisms is low(SRC). A 3% of theoretical BOD using activated sludge in the Japanese MITI test(5) suggests that biodegradation is not an important environmental fate process in water(SRC).|ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), p-toluenesulfonamide, which has an estimated vapor pressure of 9.6X10-5 mm Hg at 25 °C(SRC), determined from a fragment constant method(2), will exist in both the vapor and particulate phases in the ambient atmosphere. Vapor-phase p-toluenesulfonamide is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 13 days(SRC), calculated from its rate constant of 1.2X10-12 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(2). Particulate-phase p-toluenesulfonamide may be removed from the air by wet and dry deposition(SRC). p-Toluenesulfonamide does not absorb light at wavelengths >290 nm(3) and, therefore, is not expected to be susceptible to direct photolysis by sunlight, since sunlight consists of wavelengths above 290 nm(SRC).

The rate constant for the vapor-phase reaction of p-toluenesulfonamide with photochemically-produced hydroxyl radicals has been estimated as 1.2X10-12 cu cm/molecule-sec at 25 °C(SRC) using a structure estimation method(1). This corresponds to an atmospheric half-life of about 13 days at an atmospheric concentration of 5X10+5 hydroxyl radicals per cu cm(1). p-toluenesulfonamide is not expected to undergo hydrolysis in the environment due to the lack of functional groups that hydrolyze under environmental conditions(2). p-toluenesulfonamide does not absorb light at wavelengths >290 nm(3) and, therefore, is not expected to be susceptible to direct photolysis by sunlight, since sunlight consists of wavelengths above 290 nm(SRC).

An estimated BCF of 3.2 was calculated for p-toluenesulfonamide(SRC), using a log Kow of 0.82(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is low(SRC).

The Koc of p-toluenesulfonamide is estimated as 35(SRC), using a log Kow of 0.82(1) and a regression-derived equation(2). According to a classification scheme(3), this estimated Koc value suggests that p-toluenesulfonamide is expected to have very high mobility in soil.

The Henry's Law constant for p-toluenesulfonamide is estimated as 4.7X10-7 atm-cu m/mole(SRC) using a fragment constant estimation method(1). This Henry's Law constant indicates that p-toluenesulfonamide is expected to be essentially nonvolatile from water surfaces(2). p-Toluenesulfonamide is not expected to volatilize from dry soil surfaces(SRC) based upon an estimated vapor pressure of 9.6X10-5 mm Hg(SRC), determined from a fragment constant method(1).

GROUNDWATER: p-Toluenesulfonamide was identified in groundwater collected from 96 wells located at the drinking water treatment plant at Lake Muggelsee in Berlin Germany at concentrations between <0.05 and 41 ug/L. p-Toluenesulfonamide was identified in groundwater collected from wells located at the drinking water treatment plant Spandau in western Germany at concentrations below <0.1 ug/L(1).|DRINKING WATER: p-Toluenesulfonamide was identified, not quantified, in drinking water from Cincinnati, OH(1) and groundwater from a polluted landfill(2). p-Toluenesulfonamide was detected at 0.063 ug/L in Rhine river water at Lobith, Germany(3).

According to the 2016 TSCA Inventory Update Reporting data, 3 reporting facilities estimate the number of persons reasonably likely to be exposed during the manufacturing, processing, or use of p-toluenesulfonamide in the United States may be as low as 10 workers and as high as 24 workers per plant; the data may be greatly underestimated due to confidential business information (CBI) or unknown values(1).|NIOSH (NOES Survey 1981-1983) has statistically estimated that 9,023 workers (1,223 of these are female) were potentially exposed to p-toluenesulfonamide in the US(1). Occupational exposure to p-toluenesulfonamide may occur through dermal contact with this compound at workplaces where p-toluenesulfonamide is produced or used. Limited monitoring data indicate that the general population may be exposed to p-toluenesulfonamide via ingestion of contaminated drinking water, and dermal contact with consumer products containing p-toluenesulfonamide(SRC).

/CLINICAL TRIALS/ ClinicalTrials.gov is a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world. The Web site is maintained by the National Library of Medicine (NLM) and the National Institutes of Health (NIH). Each ClinicalTrials.gov record presents summary information about a study protocol and includes the following: Disease or condition; Intervention (for example, the medical product, behavior, or procedure being studied); Title, description, and design of the study; Requirements for participation (eligibility criteria); Locations where the study is being conducted; Contact information for the study locations; and Links to relevant information on other health Web sites, such as NLM's MedlinePlus for patient health information and PubMed for citations and abstracts for scholarly articles in the field of medicine. Para-toluenesulfonamide is included in the database.|/EXPL THER/ Severe malignant airway obstruction (SMAO) is a life-threatening form of non-small cell lung carcinoma (NSCLC). /The purpose of this study was/ to determine the efficacy and safety of para-toluenesulfonamide (PTS) intratumoral injection in NSCLC-SMAO. Ninety patients with NSCLC-SAO received repeated courses of PTS intratumoral injection until tumor sizes had reduced by 50% or greater. Primary endpoint was objective alleviation rate, assessed by chest computed tomography (CT) and bronchoscopy, at day 7 and 30 following final dosing. Secondary endpoints included airway obstruction, spirometry, quality-of-life and survival time. In full-analysis set (N=88), using RECIST criteria, PTS treatment resulted in a significant objective alleviation rate [chest CT: 59.1% (95%CI: 48.1%-69.5%), bronchoscopy: 48.9% (95%CI: 38.1%-59.8%) at day 7; chest CT: 43.2% (95%CI: 32.7%-54.2%), bronchoscopy: 29.6% (95%CI: 20.3%-40.2%) at day 30]. There was a remarkable increase in FVC (mean difference: 0.35 liters, 95%CI: 0.16-0.53 liters), FEV1 (mean difference: 0.27 liters, 95%CI: 0.07-0.48 liters), Baseline Dyspnea Index (mean difference: 64.8%, 95%CI: 53.9-74.7%) and Functional Assessment of Cancer Therapy-Lung Cancer Subscale (mean difference: 6.9, 95%CI: 3.8-9.9) at day 7 post-treatment. We noted significantly reduced prevalence of atelectasis (by 42.9%) and Eastern Cooperative Oncology Group physical performance scale (mean difference: 7.2, 95%CI: 3.9-10.5). Median survival time was 394 days in full-analysis set and 460 days in per-protocol set. Adverse events were reported in 64.0% of subjects. Seven severe adverse events (7.9%) were reported, of which three led to death (drug-related in one case). PTS intratumoral injection is effective and well tolerated for palliative therapy of NSCLC-SMAO.|/EXPL THER/ /The purpose was/ to study the effect of percutaneous para-toluenesulfonamide (PTS) injection on transplanted hepatocarcinoma in nude mice. Sixty nude mice with subcutaneous transplanted hepatocarcinoma were randomized into 6 groups, namely PTS, chemotherapy, radiotherapy, PTS+chemotherapy, PTS+radiotherapy and control groups. PTS were injected into the tumor in the nude mouse models as indicated, and the tumor growth rate and survival time of the mice were recorded. All the treatments resulted in effective arrest of the tumor growth, but the effects of PTS+chemotherapy and PTS+radiotherapy were more obvious. No significant difference in the survival time of the mice were noted between the groups. PTS+chemotherapy and PTS+radiotherapy are safe and reliable, and produces better effects than either radiotherapy or chemotherapy alone.|/EXPL THER/ Para-toluenesulfonamide (PTS) has been implicated with anticancer effects against a variety of tumors. In the present study, we investigated the inhibitory effects of PTS on tongue squamous cell carcinoma (Tca-8113) and explored the lysosomal and mitochondrial changes after PTS treatment in vitro. High-performance liquid chromatography showed that PTS selectively accumulated in Tca-8113 cells with a relatively low concentration in normal fibroblasts. Next, the effects of PTS on cell viability, invasion, and cell death were determined. PTS significantly inhibited Tca-8113 cells' viability and invasive ability with increased cancer cell death. Flow cytometric analysis and the lactate dehydrogenase release assay showed that PTS induced cancer cell death by activating apoptosis and necrosis simultaneously. Morphological changes, such as cellular shrinkage, nuclear condensation as well as formation of apoptotic body and secondary lysosomes, were observed, indicating that PTS might induce cell death through disturbing lysosomal stability. Lysosomal integrity assay and western blot showed that PTS increased lysosomal membrane permeabilization associated with activation of lysosomal cathepsin B. Finally, PTS was shown to inhibit ATP biosynthesis and induce the release of mitochondrial cytochrome c. Therefore, our findings provide a novel insight into the use of PTS in cancer therapy.|/EXPL THER/ Hepatocellular carcinoma (HCC) is difficult to eradicate due to its resilient nature. Portal vein is often involved in tumors of large size, which exclude the patient from surgical resection and local ablative therapy, such as percutaneous ethanol injection (PEI) and radiofrequency ablation (RFA) because they were considered neither effective nor safe. Currently, there is almost no effective treatment for HCC of such condition. As a unique antitumor agent in form of lipophilic fluid for local injection, para-toluenesulfonamide (PTS) produces mild side effects while necrotizing the tumor tissues quickly and efficiently. Being largely different from both PEI and RFA therapies, PTS can disseminate itself in tumors more easily than other caustic agents, such as alcohol. So PTS may offer additional benefit to HCCs with vascular involvement. We herein describe a 70-year-old HCC patient who was treated with the combination of PTS injection and transcatheter arterial chemoembolization, resulting in a significantly improved clinical prognosis.

Urinary excretion of administration p-toluenesulfonamide in rats was approx 80% with half of original compound being oxidized to p-sulfamoylbenzoic acid. More than 90% of /the p-sulfamoylbenzoic acid metabolite/ was excreted unchanged, but urine to feces ratios varied considerably among individual animals.|After oral administration of (14)C-labeled compound to rats the label was rapidly eliminated largely in urine (66-89% of dose), with little in feces (2-8% of dose). (14)C in feces was 4-sulfamoylbenzoic acid, which probably originated in tissues.

/The purpose of this study was/ to study the in vivo and in vitro metabolism and the effect of para-toluene-sulfonamide (PTS) on cytochrome P450 enzymes (CYP450). Total CYP450 and microsome protein content were determined after iv pretreatment of rats with PTS. CYP-specific substrates were incubated with rat liver microsomes. Specific CYP isoform activities were determined by using HPLC. CYP chemical inhibitors added to the incubation mixture were used to investigate the principal CYP isoforms involved in PTS metabolism. The effect of PTS on CYP isoforms was investigated by incubating PTS with specific substrates. The groups treated with 33 and 99 mg/kg per d PTS, respectively, had a total CYP content of 0.66+/-0.17 and 0.60+/-0.12 nmol/mg. The K(m) and V(max) were 92.2 umol/L and 0.0137 nmol/min per mg protein. CYP2C7, CYP2D1 and CYP3A2 might contribute to PTS metabolism in the rat liver. The inhibitory effects of sulfaphenazole and ketoconazole on PTS metabolism were shown to have a mixed mechanism, whereas PTS metabolism was inhibited noncompetitively by quinidine. PTS had little effect on the activities of the selected CYP isoforms. Generally speaking, it is relatively safe for PTS to be co-administered with other drugs. However, care should be taken when administering PTS with CYP inhibitors and the substrates of CYP2C, CYP2D and CYP3A.|Aim of this study was to investigate liver metabolism of with regard to para toluene-sulfonamide (PTS), CYP isoforms, P-glycoprotein (P-gp), and drug interactions. Known substrates, inducers and inhibitors of CYP and inhibitor of P-gp were employed and metabolites were determined with HPLC. Male Wistar rats were pretreated with ip phenobarbital (PB), ketoconazole (Ket), or verapamil (Ver) for 3 days and in situ liver perfusion of PTS was conducted in a recirculation system. Rats were also pretreated with ip PTS (33 mg/kg/day or PTS 99 mg/kg/day) for 4 days before liver perfusions with dextromethorphan (Dex) and phenacetin (Phe) preparations were conducted. Microsome incubation was used to investigate PTS effect on five CYP isoforms and PTS-drug interactions probability with phyllotoxin and 5-fluorouracil (5-FU) in vitro. PTS at 60 min perfusates had areas of 61.4% and 133.6% of the blank control in PB group and Ket group, respectively. The result that PTS metabolism was enhanced by PB and inhibited by Ket treatments suggested liver CYP was attributed to PTS metabolism. PTS mg/kg/day pretreatment slowed down the metabolism of Dex and Phe while in vitro incubations did not show a PTS (0-160 umol/L) effect on CYP activities. PTS metabolite formation when co-incubated with phyllotoxin was 50.7% of the negative control. The potent inhibitory ability of phyllotoxin to PTS requires further clinical investigation regarding in concomitant administration.|Fifteen adult rainbow trout were exposed to water solution of (14)C-tosylchloramide sodium (purity 93.7%, specific activity 1.2 ugCi/uM) at a concentration of 20 mg/L (twice the proposed treatment concentration) for a period of 1 hour and then transferred to fresh water. The temperature of the well water was 11 to 13 °C. ... tosylchloramide sodium was rapidly reduced to the primary metabolite para-toluenesulfonamide, but the levels were not quantified.|...50% of admin ortho- and para-toluenesulfonamides excreted in urine had been metabolized to ortho- and para-sulfamoylbenzoic acids, respectively.|For more Metabolism/Metabolites (Complete) data for p-Toluenesulfonamide (6 total), please visit the HSDB record page.

Fingerlings and juvenile trout were exposed to 20 mg/L (twice the therapeutic concentration) of ring UL-14C-tosylchloramide sodium (purity 93.7%, specific activity 1.2 uCi/uM) for up to 1 hr and then transferred to fresh water for recovery to assess tissue accumulation and distribution of resulting residues. The temperature of the well water was 11.6 to 12.2 °C. The estimated half-life of para-toluenesulfonamide equivalents in fingerlings was 27.3 hours whereas determined by HPLC the half-life of para-toluenesulfonamide residues in whole-body homogenates was 36.3 hours. The estimated half-life of residues in juvenile fish was 32.6 hours, based on radiometric data, while determined by HPLC the half-life for para-toluenesulfonamide residues in whole body samples was 40.3 hours.

First rinse with plenty of water for several minutes (remove contact lenses if easily possible), then refer for medical attention.

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/|/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . /Poisons A and B/|/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W TKO /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

/HUMAN EXPOSURE STUDIES/ Common contact allergen. /Toluene sulfonamide resins, from table/|/ALTERNATIVE and IN VITRO TESTS/ Para-toluenesulfonamide (PTS) has been implicated with anticancer effects against a variety of tumors. In the present study, we investigated the inhibitory effects of PTS on tongue squamous cell carcinoma (Tca-8113) and explored the lysosomal and mitochondrial changes after PTS treatment in vitro. High-performance liquid chromatography showed that PTS selectively accumulated in Tca-8113 cells with a relatively low concentration in normal fibroblasts. Next, the effects of PTS on cell viability, invasion, and cell death were determined. PTS significantly inhibited Tca-8113 cells' viability and invasive ability with increased cancer cell death. Flow cytometric analysis and the lactate dehydrogenase release assay showed that PTS induced cancer cell death by activating apoptosis and necrosis simultaneously. Morphological changes, such as cellular shrinkage, nuclear condensation as well as formation of apoptotic body and secondary lysosomes, were observed, indicating that PTS might induce cell death through disturbing lysosomal stability. Lysosomal integrity assay and western blot showed that PTS increased lysosomal membrane permeabilization associated with activation of lysosomal cathepsin B. Finally, PTS was shown to inhibit ATP biosynthesis and induce the release of mitochondrial cytochrome c. Therefore, our findings provide a novel insight into the use of PTS in cancer therapy.

4-methylbenzenesulfonamide

Redness. Pain.

Grade: Anhydrous, monohydrate, 40% aqueous solution.

Paint and coating manufacturing|Benzenesulfonamide, 4-methyl-: ACTIVE

A quantitative high-performance liquid chromatographic method for the determination of chlorpropamide, tolbutamide, and their respective hydrolysis products, p-chlorobenzenesulfonamide and p-toluenesulfonamide, in solid dosage forms was developed. The method is stability indicating and can be used to determine the sulfonamide hydrolysis product and the intact drug in the presence of minor degradates. Method reproducibility, demonstrated by repeated injections of a calibration standard, was 1.21%. The lower limit of quantitation of the hydrolysis products, p-chlorobenzenesulfonamide and p-toluenesulfonamide, was 0.2 microgram/5-microliter injection. The accuracy of the method for intact drugs was determined by comparison of the HPLC results to those obtained by the appropriate USP or BP assays. The mean of the results obtained by the two methods differed by 0.7% for chlorpropamide and 0.3% for tolbutamide. Pure drug samples were spiked with amounts of the hydrolysis products ranging from 20 to 120% of the intact content. The mean percent recovery for p-chlorobenzenesulfonamide was 98.6%; for p-toluenesulfonamide, it was 100.6%. A qualitative TLC procedure for the detection of chlorpropamide, p-chlorobenzenesulfonamide, dipropylurea, propylurea, n-propylamine, tolbutamide, p-toluenesulfonamide, dibutylurea, butylurea, and n-butylamine is also described.

Dimethylformamide dialkylacetals have been found to react readily with primary sulfonamides to form N-dimethylaminomethylene derivatives. These compounds possess excellent gas-liquid chromatographic properties and can be conveniently prepared at the submicrogram level. Their retention times are much greater than those of other sulfonamide derivatives (e.g., N,N-dimethyl) but their ease of preparation and lack of absorptive properties make them attractive for gas-liquid chromatographic studies. The practical applicability of this derivatization approach to biological studies is illustrated by the gas-liquid chromatographic determination of 3-bromo-5-cyanobenzenesulfonamide in ovine blood using 3,5-dibromobenzenesulfonamide as the internal standard. The method has a detection limit of 25 ppb with electron capture detection. /Primary sulfonamides/